2026-2027 Flu Vaccine: WHO Recommendations & Sino Biological Reagents

The landscape of influenza vaccine development is shifting as the World Health Organization (WHO) releases its recommendations for the 2026-2027 Northern Hemisphere influenza vaccine composition. These recommendations signal a demand to adapt to the evolving virus, specifically the continued dominance of a particular strain of influenza A (H3N2) and the increasing prevalence of certain B/Victoria lineage viruses. In response, Sino Biological, Inc., a company specializing in recombinant technology, has launched a new range of antigens designed to accelerate the creation of effective vaccines for the upcoming flu season.

Decoding the Viral Shift: What the WHO Recommendations Mean

Since its identification in August 2025, the H3N2 subclade K (J.2.4.1) has become the most widespread influenza A strain globally. What sets this strain apart are specific mutations – T135K and S144N – that allow it to evade the body’s immune defenses more effectively. This “immune escape,” as it’s known, prompted the WHO to select A/Darwin/1454/2025 as the new H3N2 reference virus for vaccine development, suitable for both egg-based and cell-based production methods. The H1N1 component of the vaccine is also being updated, with A/Missouri/11/2025 chosen as the new reference virus.

Alongside the changes in influenza A, activity of influenza B viruses is also on the rise. Specifically, the proportion of B/Victoria lineage viruses has increased significantly in regions like Hong Kong and the United States, jumping from 6% to over 20% recently. To address this, the WHO recommends including strains B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 in the upcoming vaccine formulation.

Sino Biological’s Response: A Comprehensive Antigen Portfolio

To support global efforts in influenza vaccine research and development, Sino Biological has introduced a comprehensive portfolio of recombinant antigens tailored to the 2026-2027 Northern Hemisphere influenza vaccine strains. These antigens include key viral components like Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP). Recombinant antigens are produced using laboratory techniques and offer a standardized, reliable source of viral proteins for vaccine development and testing.

Currently available reagents include those for the updated H1N1 strain, A/Missouri/11/2025, with HA Trimer, NA, and NP antigens readily accessible. For the dominant H3N2 subclade K, Sino Biological offers recombinant HA, NA, and NP antigens aligned with the A/Darwin/1454/2025 reference virus. Reagents for the updated B/Victoria strains, B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025, are currently in development.

A key feature of Sino Biological’s offerings is the availability of stable HA trimers. These high-purity trimers, validated by Size Exclusion Chromatography Multi-Angle Light Scattering (SEC-MALS), maintain their native conformation. This represents crucial for accurate immune characterization, allowing researchers to better understand how the vaccine will interact with the body’s immune system. Reagents like these are essential tools in the complex process of vaccine development.

Understanding Hemagglutinin (HA) and Neuraminidase (NA)

HA and NA are surface proteins on influenza viruses that play critical roles in the infection process. HA is responsible for binding to host cells, initiating infection, while NA helps release newly formed virus particles from infected cells. Because these proteins are key targets for the immune system, they are primary components of influenza vaccines. Changes in these proteins, like the mutations seen in the H3N2 subclade K, can reduce the effectiveness of existing vaccines, necessitating updates to the vaccine composition. The Centers for Disease Control and Prevention (CDC) provides detailed information on influenza viruses and their components.

The Importance of Antigenic Drift and the Need for Annual Updates

The constant evolution of influenza viruses, through a process called antigenic drift, is why annual flu vaccinations are necessary. Antigenic drift refers to the small, gradual changes in the HA and NA proteins that occur over time. These changes can allow the virus to evade the immunity developed from previous infections or vaccinations. The WHO’s recommendations for vaccine composition are based on ongoing global surveillance of circulating influenza viruses, aiming to predict which strains are most likely to be prevalent in the upcoming flu season. The WHO’s surveillance network is a critical component of global influenza preparedness.

What’s Next: Vaccine Development and Ongoing Surveillance

With the antigens now available from Sino Biological, vaccine manufacturers can begin the process of developing and producing vaccines tailored to the 2026-2027 influenza season. This process involves several stages, including antigen production, vaccine formulation, clinical trials, and regulatory review. The timeline for vaccine availability typically extends through the fall, allowing for distribution and administration before the peak of flu season.

Dr. Rob Burgess, Chief Business Officer at Sino Biological US, emphasized the company’s commitment to supporting global health preparedness, stating, “Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when infectious disease evolution threatens global health preparedness…Sino Biological remains committed to delivering reliable reagents that advance global influenza preparedness and vaccine innovation.”

Beyond vaccine development, ongoing surveillance of influenza viruses remains crucial. Continued monitoring of circulating strains will help identify any further changes that may require adjustments to the vaccine composition in future seasons. Public health agencies will continue to track influenza activity and provide updates to the public, emphasizing the importance of vaccination as the most effective way to prevent the flu and its complications.